In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Curing What Ails Alzheimer’s Drug Development

Executive Summary

Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.

You may also be interested in...



A Status Check Of The Alzheimer’s Trial Landscape

Despite high-profile failures, including the recent disappointing results for Axovant Science’s Phase III MINDSET study, the trial landscape for Alzheimer’s disease remains busy.

Gates Injects UK-US Dementia Discovery Fund With $50m And Fresh Purpose

The Dementia Discovery Fund won a $50m private investment from Bill Gates – plus his ringing support to probe beyond the amyloid beta hypothesis in hopes of eventually defeating Alzheimer's.

Amgen, Novartis May Screen 30,000 Patients To Find 2,000 For Alzheimer's Trial

A new trial for CNP520 will see if the Amgen/Novartis BACE1 inhibitor can prevent, stop or slow Alzheimer's disease progression in pre-symptomatic patients, but recruiting enough patients with the APOE4 gene will require a massive screening effort.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1128165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel